AU2002248909A1 - Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition - Google Patents

Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition

Info

Publication number
AU2002248909A1
AU2002248909A1 AU2002248909A AU4890902A AU2002248909A1 AU 2002248909 A1 AU2002248909 A1 AU 2002248909A1 AU 2002248909 A AU2002248909 A AU 2002248909A AU 4890902 A AU4890902 A AU 4890902A AU 2002248909 A1 AU2002248909 A1 AU 2002248909A1
Authority
AU
Australia
Prior art keywords
suramine
cycloserine
histidine
angiogenesis inhibition
quisqualic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002248909A
Inventor
Cynthia Carol Bamdad
R. Shoshana Bamdad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minerva Biotechnologies Corp
Original Assignee
Minerva Biotechnologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Biotechnologies Corp filed Critical Minerva Biotechnologies Corp
Publication of AU2002248909A1 publication Critical patent/AU2002248909A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Composite Materials (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
AU2002248909A 2000-11-15 2001-11-15 Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition Abandoned AU2002248909A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24886500P 2000-11-15 2000-11-15
US60/248,865 2000-11-15
US27792201P 2001-03-22 2001-03-22
US60/277,922 2001-03-22
PCT/US2001/046221 WO2002039999A2 (en) 2000-11-15 2001-11-15 Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition

Publications (1)

Publication Number Publication Date
AU2002248909A1 true AU2002248909A1 (en) 2002-05-27

Family

ID=26939634

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002248909A Abandoned AU2002248909A1 (en) 2000-11-15 2001-11-15 Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition

Country Status (3)

Country Link
US (2) US20020156112A1 (en)
AU (1) AU2002248909A1 (en)
WO (1) WO2002039999A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530432A (en) * 2000-04-12 2003-10-14 ミナーヴァ・バイオテクノロジーズ・コーポレーション Treatment of neurodegenerative diseases
ATE349011T1 (en) 2000-10-03 2007-01-15 Minerva Biotechnologies Corp MAGNETIC IN SITU DILUTION PROCESS
WO2002039999A2 (en) * 2000-11-15 2002-05-23 Minerva Biotechnologies Corporation Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
CA2428732C (en) * 2000-11-15 2018-07-31 Minerva Biotechnologies Corporation Methods and kit for simultaneous screening of interactions between a plurality of chemical or biological species and uses thereof
WO2002056022A2 (en) * 2000-11-27 2002-07-18 Minerva Biotechnologies Corp Diagnostics, drug screening and treatment for cancer
JP2004530666A (en) * 2001-03-29 2004-10-07 エモリー　ユニバーシティ Acute pharmacological enhancement of psychotherapy using learning or conditioning enhancers
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
AU2005336092B2 (en) * 2004-09-14 2010-05-27 Cynthia C. Bamdad Methods for diagnosis and treatment of cancer
ITMI20070817A1 (en) 2007-04-19 2008-10-20 Farmacetika Ltd PHARMACEUTICAL COMPOSITION INCLUDING L-CARNITINE AND AN ANTAGONIST AGENT OF MEMBRANE ADENOSIN RECEPTORS, THEIR DERIVATIVES AND / OR PHARMACEUTICALLY ACCEPTABLE SALTS, AND USE OF THE SAME IN THE PREPARATION OF DRUGS WITH NON-TOXIC EFFECT OF INIBI
KR20170110740A (en) 2008-10-09 2017-10-11 미네르바 바이오테크놀로지 코포레이션 Method for inducing pluripotency in cells
US20110245311A1 (en) * 2009-04-03 2011-10-06 Dennis Wright Histidine Derivatives
EP4086338A1 (en) 2011-03-17 2022-11-09 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
CN116199790A (en) 2015-02-10 2023-06-02 米纳瓦生物技术公司 Humanized anti-MUCl antibodies
JP2019151621A (en) * 2018-02-28 2019-09-12 学校法人藤田学園 Composition for cancer therapy containing compound having kat inhibitory activity
CN115944627A (en) * 2023-01-13 2023-04-11 山西医科大学 Pharmaceutical composition for treating breast cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153113A (en) * 1967-01-20 1969-05-21 Chugai Pharmaceutical Co Ltd Method of Treating Hemolytic Streptococci and the Resultant Preparation containing the same
US5620850A (en) * 1994-09-26 1997-04-15 President And Fellows Of Harvard College Molecular recognition at surfaces derivatized with self-assembled monolayers
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
ATE349011T1 (en) * 2000-10-03 2007-01-15 Minerva Biotechnologies Corp MAGNETIC IN SITU DILUTION PROCESS
CA2428732C (en) * 2000-11-15 2018-07-31 Minerva Biotechnologies Corporation Methods and kit for simultaneous screening of interactions between a plurality of chemical or biological species and uses thereof
WO2002039999A2 (en) * 2000-11-15 2002-05-23 Minerva Biotechnologies Corporation Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition

Also Published As

Publication number Publication date
WO2002039999A3 (en) 2003-02-20
US20020156112A1 (en) 2002-10-24
WO2002039999A2 (en) 2002-05-23
WO2002039999B1 (en) 2004-04-15
US20050014784A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
AU2001234128A1 (en) Novel imidazoline compounds
AU2002333524A1 (en) Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
AU2001256769A1 (en) Triazole derivatives
AU2002248909A1 (en) Use of suramine, l-histidine, quisqualic acid or d-cycloserine for angiogenesis inhibition
AU2001241927A1 (en) Inhibitors of p38-alpha kinase
AU2002214163A1 (en) Pyridyl-substituted triazoles as tgf inhibitors
WO2001030781A3 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
AU2002216087A1 (en) Novel substituted imidazotriazinones as pde ii-inhibitors
AU2001257521A1 (en) Prostaglandin compounds for treating congestive heart failure
AU2002216314A1 (en) Heterocyclic angiogenesis inhibitors
AU2000223275A1 (en) Novel triazole derivatives
PL355098A1 (en) Imidazole compounds used as phosphodiesterase vii inhibitors
AU3429700A (en) Substituted benzoylpyrazoles as herbicides
AU2002230531A1 (en) Use of fgf-19 for inhibiting angiogenesis
AU2001226794A1 (en) Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
MXPA03008205A (en) Process for the preparation of imidazole compounds.
AU2002356180A1 (en) Methods for inhibiting angiogenesis
AU7961300A (en) Kainic acid neurocytotoxicity inhibitors
AU2002349621A1 (en) Angiogenesis inhibitor
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU2002214976A1 (en) Process for the preparation of benzotriazoles
AU2001290254A1 (en) Imidazole derivatives or their salts
AU2110201A (en) Release coating for tapes
AU3971700A (en) Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase
AU2001295952A1 (en) Novel remedies or preventives for angiostenosis